ANEB insider transaction filings
Anebulo Pharmaceuticals, Inc. — 21 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-04-07. Screen ANEB transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ANEB between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Anebulo Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-04-07 | 4 | Calloway Nathaniel — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 3,309 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Kupchyk Areta — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 2,647 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Lin Kenneth — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 4,964 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | English Aron R. — Director, 10% owner | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 2,647 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Lawler Joseph F. — Director, 10% owner | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 13,236 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Cunningham, Richard Anthony — Chief Executive Officer, Director | Grant/award (A): 316,352 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | SHAH BIMAL R. — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 6,618 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Aryeh Jason — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 4,964 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Cundy Kenneth C — Chief Scientific Officer | Grant/award (A): 115,037 (derivative) @ $0 | EDGAR |
| 2024-12-26 | 4 | English Aron R. — Director, 10% owner 22NW Fund, LP — 10% owner | Purchase (P): 10,101,010 @ $0.99 | EDGAR |
| 2024-12-10 | 4 | Cunningham, Richard Anthony — Chief Executive Officer, Director | Grant/award (A): 254,433 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Calloway Nathaniel — Director | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 1,655 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Kupchyk Areta — Director | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 1,324 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Lin Kenneth — Director | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 2,482 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | English Aron R. — Director, 10% owner | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 1,324 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Lawler Joseph F. — Director | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 6,618 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | SHAH BIMAL R. — Director | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 3,309 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Aryeh Jason — Director | Grant/award (A): 41,667 (derivative) @ $0 · Grant/award (A): 2,482 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4/A | Cundy Kenneth C — Chief Scientific Officer | Grant/award (A): 72,613 (derivative) @ $0 | EDGAR |
| 2024-03-01 | 4 | Cundy Kenneth C — Chief Scientific Officer | Grant/award (A): 72,613 (derivative) @ $0 | EDGAR |
| 2023-12-20 | 4 | English Aron R. — Director, 10% owner 22NW, LP — 10% owner 22NW Fund, LP — 10% owner | Grant/award (A): 300,000 @ $0 · Gift (G): 300,000 @ $0 · Gift (G): 300,000 @ $0 | EDGAR |
Recent 8-K events — Anebulo Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-06 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ANEB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →